116,502 Shares in Organon & Co. $OGN Acquired by Squarepoint Ops LLC

Squarepoint Ops LLC acquired a new stake in Organon & Co. (NYSE:OGN) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 116,502 shares of the company’s stock, valued at approximately $1,128,000.

A number of other institutional investors have also recently made changes to their positions in OGN. Norges Bank purchased a new position in shares of Organon & Co. in the second quarter worth $19,778,000. AQR Capital Management LLC increased its position in shares of Organon & Co. by 136.1% in the second quarter. AQR Capital Management LLC now owns 3,254,884 shares of the company’s stock valued at $31,507,000 after acquiring an additional 1,876,264 shares during the period. Private Management Group Inc. increased its position in shares of Organon & Co. by 46.4% in the second quarter. Private Management Group Inc. now owns 3,135,960 shares of the company’s stock valued at $30,356,000 after acquiring an additional 993,950 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Organon & Co. by 870.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 1,010,789 shares of the company’s stock valued at $15,051,000 after acquiring an additional 906,675 shares during the last quarter. Finally, Brandywine Global Investment Management LLC raised its stake in shares of Organon & Co. by 58.7% during the second quarter. Brandywine Global Investment Management LLC now owns 2,262,626 shares of the company’s stock valued at $21,902,000 after acquiring an additional 837,201 shares during the last quarter. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Organon & Co. Stock Down 0.1%

OGN stock opened at $6.83 on Monday. Organon & Co. has a fifty-two week low of $6.18 and a fifty-two week high of $17.23. The company has a market capitalization of $1.78 billion, a price-to-earnings ratio of 3.56, a price-to-earnings-growth ratio of 1.46 and a beta of 0.57. The business’s 50 day moving average price is $7.59 and its two-hundred day moving average price is $9.08. The company has a debt-to-equity ratio of 9.69, a quick ratio of 1.20 and a current ratio of 1.75.

Organon & Co. (NYSE:OGN) last released its quarterly earnings results on Monday, November 10th. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.93 by $0.08. The company had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.57 billion. Organon & Co. had a return on equity of 143.47% and a net margin of 7.95%.During the same period in the previous year, the company posted $1.38 earnings per share. As a group, analysts forecast that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, December 11th. Stockholders of record on Thursday, November 20th were given a $0.02 dividend. The ex-dividend date of this dividend was Thursday, November 20th. This represents a $0.08 dividend on an annualized basis and a dividend yield of 1.2%. Organon & Co.’s dividend payout ratio is currently 4.17%.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. JPMorgan Chase & Co. cut their target price on Organon & Co. from $14.00 to $12.00 and set an “underweight” rating on the stock in a research note on Tuesday, November 11th. Barclays initiated coverage on Organon & Co. in a report on Tuesday, December 9th. They issued an “underweight” rating and a $7.50 price objective for the company. Weiss Ratings reissued a “sell (d+)” rating on shares of Organon & Co. in a research note on Wednesday, October 8th. Piper Sandler lowered Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 price target for the company. in a research note on Monday, October 27th. Finally, Morgan Stanley cut their price target on shares of Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating on the stock in a report on Tuesday, November 11th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Hold rating and four have given a Sell rating to the company. According to data from MarketBeat, Organon & Co. has a consensus rating of “Reduce” and a consensus price target of $8.38.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.